Alpha  Szenszor  Non-­‐Invasive  Diagnos.c  Sensors    

Steve  Lerner  Founder/CEO  steve@alphaszenszor.com  +1  978  371  7084  www.alphaszenszor.com      

ASI  Confiden.al  

     Highlights  

•  Alpha Szenszor Inc. provides an agnostic e-nose sensor platform based on proprietary CMOS compatible Carbon

Nanotube Technology, licensed exclusively though Nantero

•  The Company has recently formed a JV with the Technion in Israel called ‘Alnion’, addressing early stage cancer diagnostics through the emerging field of volatilomics

http://youtu.be/3l5e11B5xYI •  IEEE and Wall Street Journal ranking of IP in top 2 WW

•  Well suited for applications in medical diagnostics, wearables, environmental health monitoring and safety

ASI  Confiden.al  

ASI’s  Annual  Sensor  Chip  TAM  

Cancer

Personal Exposure Monitor

Renal Disease

Capnography

Asthma & COPD

Wearables

ASI  CNT  Sensor  

       

3  

Substance Abuse

80  BILLION

chips

570  MILLION

Chips

300  MILLION

Chips

Non Invasive Diabetes

3  BILLION Chips

3  BILLION Chips

1.2  BILLION Chips

56.2  MILLION

Chips

ASI  Confiden.al  

Team  

           

Dr.  Sarbajit  Banerjee,  PhD  

Texas  A&M,  Chemistry  

 

           

Dr.  Brent  M.  Segal,  PhD  Lockheed  Mar.n,  Nanotechnology  

                 

Prof.  Hossam  Haick,  PhD,    Prof.  Chemistry  Technion  –  Israel  (Marie  Curie  Excellence  Award,  ERC  Award  etc.)  

 

           

Dr.  Jean-­‐Frédéric  Sauniere,  MD,  PhD    

Ins.tut  Paoli  &  Calme\es  

           

Dr.  Nir  Peled,  MD,  PhD,  FCCP    Sheba  Medical  Center  

         Steve  Lerner,  CEO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  30+  years  of    Disrup.ve  Innova.on  in  Microelectronics  and    Materials.                                    Startups,  IPO,  M&A      

 

 

 

 

 

 

         Dr.  Prashanth  Makaram  PhD,  VP  Process  Development                                                                        10  years  in  electronic  materials,  Nanotechnology    

         Dr.  Claudio  Truzzi  PhD,  VP  System  Design    25  years  in  microelectronics  and  materials  technologies  

Management  Team  

Advisory  Board  

ASI  Confiden.al  

The  Nanoscale  &  CNTs  

Source: Shellzero.wordpress.com

Carbon Nanotubes •  Strongest organic

material: 5X stronger than steel

•  Near ballistic transport in metallic

•  Semiconducting CNTs have high ON-OFF ratio (~105)

•  Optimum size for detection of small concentrations of molecules

•  Selective to specific compounds when chemically programmed

ASI  Confiden.al  

e-­‐nose  Sensor  Compe..on  

Au Nano-particles, Si Nanowire

Metal Oxide Semiconductors (MOS)

Quartz Crystal Microbalance (QCM)

Colorimetric Sensor

Conductive Polymers (CP)

Gas Chromotography/ Mass Spec. (GC/MS)

Alpha SZENSZOR

(CNTs)

Sampling Non-Invasive Non-invasive Non-invasive Non-invasive Non-invasive Non-Invasive

Non-invasive

Sensitivity High (ppb) Moderate- High (sub-ppm)

Moderate (ppm)

Hign (ppb-ppm)

Moderate-high (sub-ppm)

High (ppb) High (ppb)

Power Consumption

High High High Moderate Moderate Very High Very Low

Speed Fast Moderate Moderate (~ 1 min)

Fast Fast Slow (~30 mins)

Very Fast (<30 sec)

Ease of Use Easy, no training required

Easy, no training required

Easy, no training required

Easy, no training required

Easy Needs specialized training

Easy, no specific skills required

Cost low Moderate Moderate Moderate low Very High low

Portability Yes Yes Yes No Yes No Yes

Deployment Limitations

•  Poor yielding process, bad batch reproducibility •  Hi power requirements

•  High operating temperature • high power requirement • Not suitable for VOC detection.

•  Low Signal to Noise ratios •  Complex fabrication and circuitry •  bad batch reproducibility

•  Requires sophisticated optics •  sensor cannot be reused • Non-specific for sub-histologies

•  Affected by humidity • sensor overload • limited lifetime

•  Affected by background noise and moisture •  Complex •  Nonspecific for sub-histologies

None Proven to be a Fab friendly, scalable production process

ASI  Confiden.al  

E-­‐nose  Pa\ern  Analysis  Theory    

•   The  expression  "electronic  sensing"  refers  to  the  capability  of  reproducing  human  senses  using  sensor  arrays  and  a  paWern  recogniXon  system    

•   Several  known  and  tested  pa\ern  recogni.on  algorithms  exists  and  has  been  extensively  used  for  facial  recogni.on,  finger  print  analysis,  and  electronic  nose  sensor  applica.ons  for  fruit  odors,  food  spoilage  etc.    

Pearce,  Tim  C.,  et  al.,  eds.  Handbook  of  machine  olfac0on.  Wiley.  com,  2006.  

ASI  Confiden.al  

Specificity  Techniques  

•  CNT  Surface  Func.onaliza.on:  

     1.      Metal  nano  par.cles              2.      DNA              3.      Polymers    

•  Extrac.on  of  Descriptors:  1.  Resistance  Varia.on  2.  Deriva.ve  3.  Integral    4.  Resistance  Minimum  5.  Ra.o  between  reference  and  

minimum  reference  value  

 

 1

 2

 3

 4

ASI  Confiden.al  

What  are  the  markets  saying  ?  •  “Dogs  can  do  it  but  machines  hold  the  best  hopes  

for  earlier  detec0on”    –  Cosmo  Magazine    

•  “In  5  years  computers  will  have  a  sense  of  smell….  By  capturing  the  informa0on  they  carry,  technology  can  pick  up  clues  about  your  health  and  provide  valuable  diagnos0c  informa0on  to  your  physician.”    

–  Dr.  Hendrik  F.  Hamann,  IBM  Research      (2012)  

 •  Alnion  Ranked  #1  in  “Top  10  Israeli  medical  

advances  to  watch  in  2014”.  –  Israel21C    

  ASI  Confiden.al  

High  End  App  –  Lung  Cancer  

    SensiXvity   Specificity   Accuracy   ROC  AUC  

Malignant/  Benign   86±5%   93±7%   88±2%   0.986  

Adeno/squamous   92±8%   78±7%   88±3%   0.974  

Early/Advanced  NSCLC   86±3%   88±6%   88±2%   0.961  

Peled,  N.;  Hakim,  M.;  Tisch,  U.;  Bunn,  P.  A.  Jr.  R.;  Miller,  Y.  E.;  Kennedy,  T.  C.;  Ma\ei,  J.;  Mitchell,  J.  D.;  Weyant,  M.  J.;  Hirsch,  F.  R.;  Haick,  H.*  J.  Thorac.  Oncol.  7(10),  1528-­‐1533  (2012)

Training  set:    75%  of  the  samples.    

Test  (blind)  set:    25%  of  the  samples    

ASI  Confiden.al  

Mid  Range  App  -­‐  Diabetes  

Carbon  Nanotube  Sensor  

Standard  Test  Strip  Format   Glucometer   Smartphone  or  Watch  APP    management  

S  Glucose  present  in  Saliva  correlates  with  tradi.onally  monitored  blood  glucose  levels.    

S  Mul.ple  study  groups  around  the  world  have  demonstrated  the  u.lity  of  using  saliva  for  diabetes  monitoring.  

S  Glucose  concentra.ons  in  saliva  are  100  .mes  less  than  those  in  blood  and  require  a  highly  sensi.ve  device  such  as  ASI’s  carbon  nanotube  sensor  for  accurate  detec.on.    

ASI  Confiden.al  

Recent  references  to  the  Literature  

Test  showing  correla.on  of  serum  and  salivary  glucose  level.  Abikshyeet  et.  al.  "  Diabetes,  metabolic  syndrome  and  obesity:  targets  and  therapy  5  (2012):  149.  

Carbon  Nanotube  Sensor  Detects  Glucose  in  Saliva,  MIT  Tech  Review,  Apr  30,  2013  

ASI  Confiden.al  

Low  End  App  -­‐  Wearables    Fabulyzer  measures  Acetone  in  Breath  to  monitor  Fat  Burn    -­‐ Break  down  enough  fat  and  eventually  this  compound  will  find  its  way  into  your  breath,    

-­‐ so  when  you  blow  onto  the  fat-­‐burning  breathalyzer,  you’ll  know  if  you’re  doing  enough  exercise  to  shed  off  those  extra  pounds  or  not.  

ASI  Confiden.al  

Trend  in  Breathalyzers  Today    

(Non-­‐Wearable  SoluXons)  

Kisai  Breathalyzer  

Tomorrow    (Wearable  SoluXons)  

Breathometer  (Alcohol  breathalyzer)  Raised  $2M  in  2013    

NTT  Docomo  Fat  burner  ASI  Confiden.al  

ASI  Appliance  Feasibility    

CNT Fabric Field

S D

The core technology is

based on proprietary

Carbon Nanotube IP

and Know-how

CNT sensor arrays are

manufactured and chemically programmed in

standard electronics

manufacturing environments

Low cost consumer electronics

mother board consolidates all

functions

Final appliance with wireless connection to commercially available PC, smart phone, etc.,

loaded with PRS algorithms or

downloaded from cloud

ASI  Confiden.al  

Personalized  Screening  &  Monitoring  

o Personal  breath-­‐print  in  the  cloud  

o Periodic  monitoring  &  storing  

o Trend  tracking  of  pa.ent’s  health  progression/deteriora.on  

o Early  interven.on  

o Tracking  response  to  therapeu.cs  

o Follow-­‐up  auer  surgery  

o Gene.c  muta.ons  

Comprehensive  disease  management  

Pa.ent  

Breath  Cloud  

(database)  

Age  

gender  

ethnicity   Smoking  habits  

Medica.on  

Confound-­‐ing  factors  

ASI  E-­‐Nose  Medical  Staff  

Breath  

ASI  Confiden.al  

ASI  is  currently  seeking  the  Following:  

A)  Direct  Investment  in  the  Company,  ~€2M                                                                              To  build  out  generic  chip  manufacturing  capability                          

–  The  Netherlands?  

B)  JV’s  or  Industrial  partnerships  to  address  new  applica.ons  

•  Typical  prototype  program  ~  €500K                                                          (Demonstrator  with  ISO  13485  compliant  specs.)    

•   €3M  –  €5M  Investment  to  commercialize  stand  alone  business  model:  -­‐  full  product  development  &  qualifica.on    

ASI  Confiden.al  

Summary  

•  Full  Range  of  Non-­‐Invasive  Diagnos.c  Tes.ng  

•  Dominant  IP,  as  ranked  by  IEEE  and  The  WSJ  

•  Demonstrated  Field  Data  through  Leading  Hospitals  

•  Leads  All  Compe..on  as  a  non-­‐invasive,  highly  sensi.ve,  scalable,  yet  cost  effec.ve  plaxorm  technology    

•  Rapid  .me  to  market:  1-­‐2  yrs  Consumer,  2-­‐  3  yrs  Medical      

•  Fully  Compa.ble  with  Current  Manufacturing  Supply  Chains  

ASI  Confiden.al